炎症性贫血患者的组织铁分布:一项先导研究的结果
该前瞻性队列研究采用MRI R2*弛豫测量法分析炎症性贫血(AI)患者脾、肝、胰、心铁含量,纳入2020年5月至2022年1月住院的AI患者(含合并真性缺铁者AI+IDA),对照组为无炎症个体。铁蛋白>200 μg/L的AI患者脾R2*(47.6 s-1 vs 19.3 s-1,p<.001)和胰腺R2*(32.5 s-1 vs 24.9 s-1,p=.011)显著高于对照组,肝、心R2*无差异;脾R2*升高与铁蛋白、hepcidin、CRP、IL-6浓度升高相关。AI患者恢复后脾R2*恢复正常(23.6 s-1 vs 47.6 s-1,p=.008),基线AI+IDA患者无变化。
要点
- 铁蛋白≤200 μg/L的AI+IDA患者脾R2*与对照组相当
- 铁蛋白>200 μg/L的AI患者脾和胰腺R2*显著高于对照组
- 脾R2*与铁蛋白、hepcidin、CRP、IL-6浓度升高相关
核心结论
- 本研究首次探讨炎症性贫血及合并真性缺铁的AI患者的组织铁分布,结果支持动物模型中发现炎症状态下铁主要滞留于脾脏巨噬细胞的结论。
- MRI相关铁测量可能有助于更好表征实际铁需求并定义AI患者真性缺铁诊断的更好生物标志物阈值。
- MRI铁测量可能成为评估铁补充需求和指导治疗的有用诊断方法。
研究设计与样本
- 前瞻性队列研究,采用MRI R2*弛豫测量法分析AI患者脾、肝、胰、心铁含量。
- 纳入2020年5月至2022年1月住院的AI患者,包括合并真性缺铁者(AI+IDA)。
- 对照组为无炎症个体。
主要发现
- 铁蛋白≤200 μg/L的AI+IDA患者脾R2*值与对照组相当。
- 铁蛋白>200 μg/L的AI患者脾R2*值显著高于对照组(47.6 s-1 vs 19.3 s-1,p<.001)。
- 铁蛋白>200 μg/L的AI患者胰腺R2*值显著高于对照组(32.5 s-1 vs 24.9 s-1,p=.011)。
- 铁蛋白>200 μg/L的AI患者肝和心脏R2*值与对照组无差异。
- 较高脾R2*值与较高铁蛋白、hepcidin、CRP和IL-6浓度相关。
临床怎么用
- 作者认为MRI相关铁测量可能有助于更好表征实际铁需求并定义AI患者真性缺铁诊断的更好生物标志物阈值。
- 作者认为MRI铁测量可能成为评估铁补充需求和指导治疗的有用诊断方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia of inflammation (AI) is frequently present in subjects with inflammatory disorders, primarily caused by inflammation-driven iron retention in macrophages. So far, only limited data on qualitative and quantitative estimates of tissue iron retention in AI patients exist. We performed a prospective cohort study analyzing splenic, hepatic, pancreatic, and cardiac iron content with MRI-based R2*-relaxometry in AI patients, including subjects with concomitant true iron deficiency (AI+IDA) hospitalized between 05/2020-01/2022. Control groups were individuals without inflammation. Spleen R2* values in AI patients with ferritin ≤200 μg/L (AI+IDA) were comparable with those found in controls. In AI patients with ferritin >200 μg/L, spleen (47.6 s-1 vs. 19.3 s-1 , p < .001) and pancreatic R2* values (32.5 s-1 vs. 24.9 s-1 , p = .011) were significantly higher compared with controls, while liver and heart R2*-values did not differ. Higher spleen R2* values were associated with higher ferritin, hepcidin, CRP, and IL-6 concentrations. Spleen R2* values normalized in AI patients after recovery (23.6 s-1 vs. 47.6 s-1 , p = .008), while no changes were found in patients with baseline AI+IDA. This is the first study investigating tissue iron distribution in patients with inflammatory anemia and AI with concomitant true iron deficiency. The results support the findings in animal models demonstrating iron retention in macrophages, which are primarily accumulating in the spleen under inflammatory conditions. MRI-related iron measurement may help to better characterize actual iron needs and to define better biomarker thresholds in the diagnosis of true ID in patients with AI. It may qualify as a useful diagnostic method to estimate the need for iron supplementation and to guide therapy.
引用
- Lanser L, Plaikner M, Schroll A, et al. Tissue iron distribution in patients with anemia of inflammation: Results of a pilot study. Am J Hematol. 2023. PMID: 36880875. doi:10.1002/ajh.26909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。